activated T cells and a small subset of normal resting T cells, but not with resting B cells or any of the 29 established human permanent cell lines tested. Immunohistological analysis of a wide spectrum of human tissues showed that Ber-ACT8 reactivity is restricted to a few T cells in the peripheral blood, the extrafollicular areas of lymph nodes and tonsils, and splenic red pulp. In the gut Ber-ACT8 labelled most intraepithelial T cells and up to 50% of lamina propria T cells. The antibody also immunostained T cells present in the oral and bronchial mucosa. Double labelling on splenic cells, fresh blood lymphocytes, and in vitro activated T cells showed that most Ber-ACT8 positive cells coexpressed CD8. Ber-ACT8 did not react with any of the 14 Hodgkin's lymphomas nor any of the 172 non-Hodgkin's lymphomas tested, with the exception of 10 cases of T cell lymphomas, five of which were located in the jejunum and associated with coeliac disease, and one B cell lymphoma, and most cases of hairy cell leukaemia tested. Parallel immunostainings with Ber-ACT8, anti-TCR-f (#F1), and anti-TCR-3 showed that most Ber-ACT8 positive T cells carry the TCR of a4 type. Comparison of Ber-ACT8 with HML-1, B-ly7, and LF61 showed essentially the same reactivity and an identical molecular target. Only a small number of true activation markers have been detected-that is, antigens that are absent from all non-lymphoid cells and from peripheral resting T and B cells, as well as precursor T and B cells, but expressed on in vitro activated (by lectins or viruses) and in vivo activated T and B cells. At the recent International Conference on Leucocyte Differentiation Antigens, held in Vienna in February 1989, only four antigens-CD25,'2 CD30,34 CD69,5 and CDw7O6 fulfilled the aforementioned criteria. Common features of all four of these activation markers are that they can be induced on B and T cells and on CD4 and CD8 subsets of T cells. At present, there is no known activation molecule whose expression is restricted to a defined subset of activated B or T cells.7 This prompted us to continue our search for further activation markers using a newly established HTLV-1 positive cell line (MAPS16) and monoclonal antibodies. Among the many monoclonal antibodies obtained, there was one designated Ber-ACT88 which recognises an antigen that is expressed on all in vitro activated CD8 T cells, but which is absent from most in vitro activated CD4 T and in vitro B cells.
Methods

IMMUNISATION AND SOMATIC CELL HYBRIDISATION
Eight week old female Balb/c mice were immunised intraperitoneally with 2 x 107 MAPS 16 cells suspended in phosphate buffered saline (Gibco) and Freund's complete or incomplete adjuvants at seven day intervals for 6 weeks. A final boost without adjuvants was given three days before the spleens were removed. The human T cell line MAPS Immunoprecipitates were dissolved in 90 M1 of a 1 M TRIS-HCL buffer (pH 6-8) containing 0-3% sodium dodecyl sulphate, 10% glycerol, and 5% mercaptoethanol, and boiled for five minutes. After centrifugation the supernatant was removed and split into 30 p1 aliquots. One aliquot was incubated in a buffer containing 10% n-octylglucoside, 0 1 M McIlvaine buffer (sodium citrate-phosphate buffer) pH 5-5, 50 mM EDTA (Merck), and 10 mM 1 10-phenanthroline hydrate (Sigma) and 30 units/ml endoglycosidase F (Boehringer, Mannheim) for 24 hours at 37°C. The second aliquot was incubated in a buffer containing 0.01 M calcium acetate, 0-02 M sodium cacodylate buffer (pH 6-5), 0 1 U neuraminidase (Boehringer, Mannheim) and 25 mU 0-glycanase (Genzyme) for 24 hours at 37°C.
The third aliquot was used as a control and was incubated for 24 hours at 37°C in 30 pl of a 1 M TRIS-HCL buffer (pH 6 8) without enzymes. The incubated aliquots were analysed by 8 5% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).
PURIFICATION OF THE Ber-ACT8 ANTIGEN BY AFFINITY CHROMATOGRAPHY
The Ber-ACT8 antigen was purified by affinity chromatography on protein A sepharose and coupled to CNBr-activated sepharose at 5 mg Ig/ml gel. An NP40 extract of membranes prepared from frozen specific tissue from cases of hairy cell leukaemia was passed through a column of Ber-ACT8 sepharose and the bound proteins eluted with glycine buffer pH 2 5 containing 0 5% NP40. Eluted material was analysed by SDS-PAGE and the gel stained with Coomassie Blue. Substitution of pH 2-5 elution buffer with 10 mM EDTA was used to dissociate the antigen subunits on the antibody column. Material eluted from a Ber-ACT8 column was radioiodinated and purified on an SDS-PAGE gel. Material eluted from excised gel bands was used for protease V8 and trypsin digestion, and the resulting fragments were analysed by SDS-PAGE. CD22/ Ber-ACT8   0  0  0  0  0  0  0  0  0  0  CD22/B-ly7  0  0  0  0  0  0  0  0  0  0  CD3/Ber-ACT8  3  1  4  2  3  2  1  2  2  3   CD3/B-ly7   3  1  3  2  2  2  1  1 5 MAPS 16 cells, and a significant proportion of splenic red pulp lymphocytes. One of these two clones was designated Ber-ACT8, and chosen for further characterisation: its isotype is IgG1.
REACTIVITY OF Ber-ACT8 WITH NORMAL AND ACTIVATED PERIPHERAL BLOOD CELLS Figure 1A shows that Ber-ACT8 did not react with fresh blood monocytes or granulocytes. Among the lymphocytes, only a small proportion (varying between 0-1%-2%, depending on the donor) were positive. In double colour immunofluorescence studies the Ber-ACT8 positive fresh blood lymphocytes also bound to CD3 and CD8, but not to CD4 or B cell antibodies (table 2) . Reactivity of up to 50% of T cells with Ber-ACT8 could be induced by stimulating the T lymphocytes with PHA or ConA. The first Ber-ACT8 positive T blasts appeared on the third day ( fig 1B) and disappeared between the 15th and 17th days after stimulation ( fig 1B) . Flow cytometric double immunofluorescence labelling experiments with various pairs of monoclonal antibodies showed that 80-90% of Ber-ACT8 totally inhibited labelling of the cells, while a control antibody did not. Preincubation with B-ly7 and LF61 abolished labelling, but HML-1 did not. This indicates that Ber-ACT8, B-ly7, and LF61 cross-block each other, but that HML-1 and Ber-ACT8 do not.
IMMUNOBIOCHEMICAL STUDIES
The lysate of surface iodinated cells of the T cell lines MAPS 16 ( fig 4) and HUT-EBV1 and of hairy cell leukaemia ( fig 5) were precipitated with Ber-ACT8, HML-1, B-ly7 and LF61 (the last not shown). SDS-PAGE of all immunoprecipitates gave an identical pattern, showing 2 major bands of 150 and 125 kilodaltons, and a minor component of 105 kilodaltons under reducing conditions. Under non-reducing conditions the components showed a slightly higher molecular mass (170, 140, and 120 kilodaltons). In some experiments a weak band of 210 kilodaltons was precipitated.
In sequential immunoprecipitation experiments extensive removal of the radiolabelled
Ber-ACT8 antigen with Ber-ACT8 led to a subsequent lack of reactivity for HML-1 and B-ly7, and vice versa (data not shown). Unspecific loss of reactivity was ruled out by using an anti-IL-2 receptor antibody, which still precipitated the IL-2 receptor antigen after absorption (fig 6) . Unlabelled material from hairy cell leukaemia cells prepared by affinity chromatography on a Ber-ACT8-sepharose column, when eluted under conditions of low pH, comprised material of 150 and 105 kilodaltons (reduced). The 105 kilodalton material could be eluted with EDTA, while the column retained the 150 kilodalton material (data not shown). This suggests that Ber-ACT8 recognises the 150 kilodalton protein chain. The 150 and 105 kilodalton bands produced distinct fragments when separately subjected to V8 protease or trypsin treatment.
To determine the degree and type of glycosylation of the Ber-ACT8 molecule, immunoprecipitates were treated with endoglycosidase F, or 0-glycanase and neuraminidase. Incubation with 0-glycanase and neuraminidase reduced the molecular mass of the 150 kilodalton protein by 10, whereas endoglycosidase F had no effect on the electrophoretic mobility.
To elucidate the -biosynthesis of the Ber-ACT8 antigen HUT-EBV1 cells were pulse labelled with [35S] methionine for 30 minutes. Samples of cells were taken 0, 15, 30, 60, 120 and 300 minutes after the start of the labelling. One 150 kilodalton band could be detected at the beginning of the chase time. After a chase time of 15 minutes, one additional band of 125 kilodaltons became visible. Identical results were obtained after prolongation of the chase time to 300 minutes-that is, the 150 and the 125 kilodalton bands remained unchanged.
Discussion
We have reported on the production of a new monoclonal antibody designated Ber-ACT8, with specificity for an antigen associated with lymphoid activation and gut mucosa T cells. The most relevant features of Ber-ACT8 are as follows: 1 It recognises a molecule or molecules consisting of three constant components of 150, 125 and 105 kilodaltons as shown by investigation of externally labelled cells. In a preparation of hairy cells the two components of 150 and 105 kilodaltons seem to be non-covalently linked in a way dependent on divalent cations, and the 150 kilodalton band carries the Ber-ACT8 reactive epitope, because the smaller component can be eluted from the antibody affinity column in the presence of EDTA. Peptide mapping of these two bands showed different proteolytic fragments, indicating that they represent different polypeptide chains. Enzymatic digestion studies showed that the 150 kilodalton molecule contains a small proportion (less than 10%) of 0-linked carbohydrates and sialic acid residues.
Pulse chase experiments showed that the major 150 kilodalton component and the 125 kilodalton band of the Ber-ACT8 molecule are rapidly synthesised and do not have a precusor molecule. The synthesis of the 105 kilodalton band could not be clarified by the investigations performed. 2 Ber-ACT8 reacts with 1-3% of fresh, peripheral blood CD8 T cells, but not with peripheral blood granulocytes, monocytes, CD4 positive T cells and B cells. This finding was confirmed by a subsequent and independent study.2' Our studies further showed that Ber-ACT8 strongly binds to nearly all activated CD8 T cells, but remained unreactive with more than 80% of activated CD4 T cells and most B cells. Ber-ACT8 also reacts weakly with most monocytes activated by adherence. None of the presently known activation antigens show similar restriction in their expression to activated CD8 positive T cells. The Ber-ACT8 molecule appears on CD8 positive T cells relatively late following the activation stimulus-that is, on the third day, and reaches its peak of expression on the seventh and eighth days, disappearing between the 15th and 18th days. In this respect the Ber-ACT8 antigen is reminiscent of the very late activation (VLA) antigens. 22 3 With the exception of the two newly established cell lines MAPS16 and HUT-EBV1, Ber-ACT8 does not stain any of the many known cell lines studied, in contrast to all other antibodies to activation antigens (such as CD25, CD30, CD69, CDw7O), which are positive on many lymphoid cell lines. 4 In lymph nodes and tonsils Ber-ACT8 labels few small lymphoid cells in the paracortical region and follicle mantle, as well as within the oral mucosa. In the spleen it stains only lymphoid cells in the red pulp and the T region of the white pulp. This distribution pattern of the Ber-ACT8 positive cells in tonsils, lymph nodes, and spleen coincides with that seen with CD8. The difference is that CD8 stains more T cells and, in the spleen, sinus lining cells as well. By double labelling of suspended splenic cells, it could be shown that most Ber-ACT8 positive cells were also CD8 positive, indicating that a proportion of the red pulp CD8 T cells also express the antigen detected by Ber-ACT8. Studies of extranodal lymphoid tissue showed that Ber-ACT8 stains more than 90% of intraepithelial lymphocytes and 20-50% of lamina propria T cells in the small intestine. In other intraepithelial layers such as oral mucosa and bronchial epithelium, Ber-ACT8 also stains most T cells. Double labelling adjacent sections of lymph nodes, tonsils, small intestine, bronchial epithelium and other tissues with Ber-ACT8 and Ki-67, directed at a proliferation-associated nuclear antigen, showed that nearly all Ber-ACT8 positive cells in the organs mentioned were in a resting phase. This indicates that the expression of the Ber-ACT8 antigen is not only induced by activation events, but seems to be regulated by special tissue environmental signals.
Apart from the above mentioned lymphoid cells, Ber-ACT8 also weakly stains in vitro activated monocytes and some in vivo activated macrophages-that is, some epithelioid type macrophages and macrophages in some malignant lymphomas. No other cells of any other tissues are reactive with Ber-ACT8. 5 Extension of the studies to malignant lymphomas showed that Ber-ACT8 reactivity among T cell lymphomas is restricted to extranodal types, occurring in the vocal cords, mesenterium, and jejunum-the latter being associated with enteropathy. Ber-ACT8 proved negative with all B cell lymphomas except one extranodal B cell lymphoma of centroblastic morphology and 12 cases of hairy cell leukaemia. Of interest is the non-reactivity of Ber-ACT8 with anaplastic large cell lym- were not totally congruent with those found for the Ber-ACT8 antigen, the similarities were sufficient to encourage us to compare HML-1 and B-1y7 with Ber-ACT8. Both HML-1 and B-ly7 produced a very similar immunostaining in normal and pathological tissues as well as with fresh resting blood lymphocytes and lectin-stimulated blood T cells. We have described the latter reactivity of HML-1.27 While the staining results with Ber-ACT8 and B-ly7 were identical, HML-1 differed slightly from the two other monoclonal antibodies in that it stained more strongly and a higher percentage of in vivo and in vitro activated macrophages. The similar reactivity of the antibodies was confirmed by the indistinguishable immunoprecipitation patterns of all three monoclonal antibodies. Sequential immunoprecipitation proved that all three antibodies (Ber-ACT8, B-ly7, and HML-1) react with the same 150/ 125/105 kilodalton molecular structure. In subsequent experiments we showed that the antibody LF6 120 is also reactive with the same trimeric antigen. Cross-blocking experiments showed that Ber-ACT8, B-ly7, and LF61 bind to the same or neighbouring epitopes, and HML-1 to a second epitope. This finding might explain the slightly different labelling reactivity of HML-1.
Recently, the selective reactivity of the monoclonal HML-1 with coeliac disease associated T cell lymphomas of the gut was challenged.28 With the new monoclonal Ber-ACT8, which reacts considerably more weakly with activated macrophages, however, we confirmed the absence of the molecule recognised by HML-l/Ber-ACT8 from all lymph nodal peripheral T cell lymphomas. The frequent reactivity of lymph nodal T cell lymphomas described by Pallesen et al28 thus seems to have been due to the use of sticky HML-1 ascites,29 or to positively labelled macrophages erroneously regarded as tumour cells.
In a recent study30 B-ly7 was reported to be reactive with a case of adult T cell leukaemia and a case of Sezary's syndrome. These findings are no different to those presented here or in a previous study because we also observed reactivity of Ber-ACT8 and HML-13' with some cases of cutaneous T cell lymphomas, exhibiting a preferentially base layer localised epidermotropism.
To clarify the marker importance and the functional properties of the Ber-ACT8 reactive molecule its expression was correlated in a parallel study2" with the presence of adhesion molecules (homing receptors), markers of maturation and previous activation, and the skin tissue association molecule CLA (cutaneous lymphocyte antigen).32 These studies showed that, with Ber-ACT8 and HECA-452 to CLA, three non-overlapping blood T cell populations (Ber-ACT8+, CLA-: 1-3%; Ber-ACT8-, CLA+: 10-15 %; Ber-ACT8 ,CLA-: 80-90%) can be defined, whereby the Ber-ACT8 positive T cells differ from the other T cell subsets in that the Ber-ACT8 positive T cells bear homing receptors for gut mucosal tissue but not for peripheral lymph nodes, that the Ber-ACT negative T cells carry receptors for peripheral lymph nodes but not for mucosal tissue, and that the Ber-ACT8 positive T cells are found predominantly, if not exclusively, in the memory or previously activated T cell subset. These findings are consistent with a mucosal derivation or mucosal homing preference of the peripheral blood Ber-ACT8 positive T cells, and make the reactivity of intestinal T cell lymphomas with Ber-ACT8 understandable. As a result of these findings, it has been proposed that the Ber-ACT8/B-ly7/ HML-1/LF61 reactive molecule should be designated as mucosa lymphocyte antigen (MLA).2' The clinical importance of MLA expression on the tumour cells of some cases of cutaneous T cell lymphomas and hairy cell leukaemia remains to be determined. The data presented in this paper strongly suggest-in contrast to the paper by Visser et al '9-that normal MLA positive blood lymphocytes are not the long sought physiological equivalents of hairy cell leukaemia cells because MLA positive blood cells have a T cell and not a B cell phenotype.
